Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

BACKGROUND & AIMS: Two SARS-CoV-2 mRNA vaccines were approved to prevent COVID-19 infection, with reported vaccine efficacy of 95%. Liver transplant (LT) recipients are at risk of lower vaccine immunogenicity and were not included in the registration trials. We assessed vaccine immunogenicity an...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Hepatol
Главные авторы: Rabinowich, Liane, Grupper, Ayelet, Baruch, Roni, Ben-Yehoyada, Merav, Halperin, Tami, Turner, Dan, Katchman, Eugene, Levi, Sharon, Houri, Inbal, Lubezky, Nir, Shibolet, Oren, Katchman, Helena
Формат: Artigo
Язык:Inglês
Опубликовано: European Association for the Study of the Liver. Published by Elsevier B.V. 2021
Предметы:
Short Communication
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8058047/
https://ncbi.nlm.nih.gov/pubmed/33892006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2021.04.020
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы